Cystathionase Inhibitors
1 drugsAbout Cystathionase
Cystathionase is an enzyme with potential as a drug target, though its precise role in disease is still under investigation.
Currently, there is no genetic evidence directly linking Cystathionase to specific diseases, representing an area for further research.
ELCYS, a small molecule drug targeting Cystathionase, has been FDA-approved since 2019 for one indication in the 'Other' therapeutic area.
Top Cystathionase Drugs
EXELA PHARMA is the only company with an approved drug targeting Cystathionase.
The lack of competition suggests a high-risk, high-reward market entry scenario.
Cystathionase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Cystathionase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Cystathionase Drug Approval Timeline (2019 - 2019)
The first and only drug, ELCYS, was approved in 2019.
The recent approval suggests potential for further drug development in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline